

Taro Okamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/236395/publications.pdf>

Version: 2024-02-01

10
papers

194
citations

1477746

6
h-index

1281420

11
g-index

11
all docs

11
docs citations

11
times ranked

257
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. <i>Endocrine Journal</i> , 2010, 57, 383-394.	0.7	90
2	Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. <i>Diabetology International</i> , 2013, 4, 160-172.	0.7	23
3	Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2013, 4, 595-604.	1.1	21
4	A randomized, placebo- and sitagliptin- controlled trial of the safety and efficacy of omarigliptin, a once- weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1602-1609.	2.2	19
5	Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1033-1041.	2.2	18
6	A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control. <i>Diabetes Therapy</i> , 2017, 8, 793-810.	1.2	5
7	Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2099-2108.	2.2	5
8	A randomized, placebo- controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1242-1251.	2.2	4
9	A randomized, placebo- controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1342-1350.	2.2	2
10	Factors associated with the glucose- lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials. <i>Journal of Diabetes Investigation</i> , 2020, 11, 640-646.	1.1	1